These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24564776)

  • 1. [Vitamin D in relation to head and neck cancer].
    Kalfeřt D; Ludvíková M; Pešta M; Topolčan O
    Vnitr Lek; 2014 Jan; 60(1):51-8. PubMed ID: 24564776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vitamin D relation to the head and neck cancer].
    Neuwirthová J
    Vnitr Lek; 2014 Jan; 60(1):20-1. PubMed ID: 24683669
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.
    Starska-Kowarska K
    Nutrients; 2023 May; 15(11):. PubMed ID: 37299554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
    Satake K; Takagi E; Ishii A; Kato Y; Imagawa Y; Kimura Y; Tsukuda M
    Auris Nasus Larynx; 2003 Dec; 30(4):403-12. PubMed ID: 14656567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
    Sivanantham B; Sethuraman S; Krishnan UM
    ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MART-10, a newly synthesized vitamin D analog, represses metastatic potential of head and neck squamous carcinoma cells.
    Yang SW; Tsai CY; Pan YC; Yeh CN; Pang JH; Takano M; Kittaka A; Juang HH; Chen TC; Chiang KC
    Drug Des Devel Ther; 2016; 10():1995-2002. PubMed ID: 27382252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase.
    Chiang KC; Yeh CN; Hsu JT; Chen LW; Kuo SF; Sun CC; Huang CC; Pang JH; Flanagan JN; Takano M; Kittaka A; Juang HH; Yang SW; Chen TC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():427-34. PubMed ID: 24044969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
    Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
    BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
    Song Q; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review.
    Pavan LM; Rêgo DF; Elias ST; De Luca Canto G; Guerra EN
    PLoS One; 2015; 10(6):e0130476. PubMed ID: 26098683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
    Yang Y; Yan J; Huang Y; Xu H; Zhang Y; Hu R; Jiang J; Chen Z; Jiang H
    Biomed Pharmacother; 2015 Mar; 70():181-9. PubMed ID: 25776499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
    Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
    Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts.
    Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M
    Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.